The principle of pro-drug in drug design
Guo, Z.R.
Yao Xue Xue Bao 14(9): 566-576
1979
ISSN/ISBN: 0513-4870 PMID: 532661 Document Number: 149072
Document emailed within 1 workday
Related Documents
Ayala, R.C.; Arya, V.; Younis, I.R. 2016: Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives Journal of Clinical Pharmacology 56(5): 541-547Guo, Z.-r. 2008: Strategy of molecular drug design: hits, leads and drug candidates Yao Xue Xue Bao 43(9): 898-904
Kutter, E.; Austel, V. 1981: Application of the theory of sets to drug design. Development of a new cardiotonic drug AR-L 115 BS Arzneimittel-Forschung 31(1a): 135-141
Kashyap, A.; Singh, P.Kumar.; Silakari, O. 2018: Counting on Fragment Based Drug Design Approach for Drug Discovery Current Topics in Medicinal Chemistry 18(27): 2284-2293
Luna, D.; Otero, C.; Risk, M.; Stanziola, E.; González Bernaldo de Quirós, Fán. 2016: Impact of Participatory Design for Drug-Drug Interaction Alerts. A Comparison Study Between Two Interfaces Studies in Health Technology and Informatics 228: 68-72
Luna, D.R.; Rizzato Lede, D.A.; Rubin, L.; Otero, C.M.; Ortiz, J.M.; García, Mónica.G.; Rapisarda, R.P.; Risk, M.R.; González Bernaldo de Quirós, Fán. 2017: User-Centered Design Improves the Usability of Drug-Drug Interaction Alerts: A Validation Study in the Real Scenario Studies in Health Technology and Informatics 245: 1085-1089
Smith, D.A.; Jones, B. 1999: Variability in drug response as a factor in drug design Current Opinion in Drug Discovery and Development 2(1): 33-41
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Jenke, D. 2010: Application of Quality by Design (QbD) Principles to Extractables/Leachables Assessment. Establishing a Design Space for Terminally Sterilized Aqueous Drug Products Stored in a Plastic Packaging System PDA Journal of Pharmaceutical Science and Technology 64(6): 527-535
Nishikaze, O. 1975: Drug-drug interaction and drug-induced interference with clinical laboratory test procedures--chairman's introductory remarks Rinsho Byori. Japanese Journal of Clinical Pathology 23(2): 75
Makino, K.; Idenuma, R.; Murakami, T.; Ohshima, H. 2001: Design of a rate- and time-programming drug release device using a hydrogel: pulsatile drug release from kappa-carrageenan hydrogel device by surface erosion of the hydrogel Colloids and Surfaces. B Biointerfaces 20(4): 355-359
Eisenbrand, G.; Müller, N.; Schreiber, J.; Stahl, W.; Sterzel, W.; Berger, M.R.; Zeller, W.J.; Fiebig, H. 1986: Drug design: nitrosoureas Iarc Scientific Publications 78: 281-294
Zhang, Z.-H.; Jin, J.; Zhang, H.-W.; Xin, W.; Jia, G.-B.; Wu, W.-F.; Pan, W.-S. 2011: Design push-pull osmotic pump tablets of famotidine based on an expert system for the formulation design of osmotic pump of poor water-soluble drug Yao Xue Xue Bao 46(1): 109-114
Matsuda, T. 1993: Antithrombotic drug (thrombolytic drug, anticoagulant, antiplatelet drug) Nihon Rinsho. Japanese Journal of Clinical Medicine 51 Suppl: 179-185
Akagi, R. 2007: Metabolism of heme and novel drug design Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 130(4): 247
Bernstein, J. 1989: Polymorphism in drug design and delivery Progress in Clinical and Biological Research 289: 203-215
Hara, H. 2011: Paradigm shift in drug design Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 138(4): 133-134
Nivet, J.M. 1996: Statistic determination of release limits of a finished product active principle compared to drug specification at peremption and eventually at the end of its after reconstitution Annales Pharmaceutiques Francaises 54(3): 131-139
Wlodawer, A. 1994: Rational drug design: the proteinase inhibitors PharmacoTherapy 14(6 Pt 2): 9S
Kohl, C.; Steinkellner, M. 2000: Prediction of pharmacokinetic drug/drug interactions from in vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants Drug Metabolism and Disposition: the Biological Fate of Chemicals 28(2): 161-168